Karyopharm Therapeutics Inc. is facing significant challenges as it prepares to be delisted from Nasdaq due to its recent Chapter 11 bankruptcy filing. This decision, effective November 11, 2026, underscores the financial difficulties the company is experiencing and highlights the ongoing struggles within the pharmaceutical preparations industry.

The company filed for bankruptcy on November 2, 2026, marking a critical turning point in its operations. The delisting from Nasdaq was confirmed in a notice received on November 4, 2026, which cited the bankruptcy filings and public interest concerns as key factors in the decision.

Background

Karyopharm Therapeutics Inc., incorporated in Delaware, operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company trades under the ticker symbol KPTI on the Nasdaq Global Select Market. Its recent filings indicate a series of financial challenges leading up to the bankruptcy petition.

What the Filing Says

The filing states, "As previously disclosed, on November 2, 2026, Karyopharm Therapeutics Inc. and its subsidiary, KPT Texas LLC, filed voluntary petitions under Chapter 11 of title 11 of the United States Code." The notice from Nasdaq confirmed that the company’s securities would be delisted due to the bankruptcy and related concerns.

Impact

The delisting will affect Karyopharm's shareholders, who are cautioned about the speculative nature of trading during the bankruptcy proceedings. The filing warns that existing equity securities may have no value, and shareholders could face substantial losses. The company’s transition to over-the-counter trading under the symbol KPTIQ is expected to begin on or after November 11, 2026.

What's Next

Following the delisting, the company will not appeal Nasdaq's determination. A Form 25-NSE will be filed with the SEC to formally remove the securities from listing and registration on Nasdaq. The filing does not specify what further actions will be taken beyond this transition.